Prothena Corp PLC
Company Profile
Business description
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Contact
77 Sir John Rogerson’s Quay
Block C
Grand Canal Docklands
Dublin 2D02 VK60
IRLT: +353 12362500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
163
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,826.70 | 48.80 | 0.56% |
CAC 40 | 7,902.25 | 23.79 | 0.30% |
DAX 40 | 24,456.81 | 92.75 | -0.38% |
Dow JONES (US) | 44,705.19 | 246.89 | 0.56% |
FTSE 100 | 8,975.66 | 108.64 | 1.23% |
HKSE | 24,028.37 | 136.05 | 0.57% |
NASDAQ | 20,646.36 | 35.03 | 0.17% |
Nikkei 225 | 39,646.36 | 174.92 | -0.44% |
NZX 50 Index | 12,760.20 | 8.41 | -0.07% |
S&P 500 | 6,285.19 | 21.93 | 0.35% |
S&P/ASX 200 | 8,589.20 | 50.60 | 0.59% |
SSE Composite Index | 3,509.68 | 16.63 | 0.48% |